Equities Analysts Issue Forecasts for Enovis Q4 Earnings

Enovis Co. (NYSE:ENOV) – William Blair reduced their Q4 2024 earnings estimates for shares of Enovis in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.95. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis’ Q4 2025 earnings at $0.96 EPS.

A number of other equities analysts have also weighed in on ENOV. JPMorgan Chase & Co. dropped their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Evercore ISI cut their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities began coverage on Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Trading Down 0.9 %

Shares of NYSE:ENOV opened at $46.91 on Monday. Enovis has a 12-month low of $38.27 and a 12-month high of $65.03. The company has a market cap of $2.62 billion, a PE ratio of -21.42 and a beta of 1.91. The stock has a 50 day moving average of $42.29 and a 200 day moving average of $45.32. The company has a current ratio of 2.27, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.56 earnings per share.

Institutional Trading of Enovis

A number of large investors have recently added to or reduced their stakes in ENOV. River Road Asset Management LLC purchased a new position in shares of Enovis in the third quarter valued at $51,341,000. American Century Companies Inc. grew its stake in shares of Enovis by 78.6% in the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after buying an additional 665,208 shares in the last quarter. Magnetar Financial LLC raised its position in shares of Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after buying an additional 442,051 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its holdings in shares of Enovis by 14.5% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after acquiring an additional 352,116 shares during the last quarter. Finally, Royce & Associates LP grew its position in Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after acquiring an additional 346,317 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.